Generex Biotechnology Corporation is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device.
Revenue (Q2, 2018)
Net income (Q2, 2018)
EBIT (Q2, 2018)
Market capitalization (31-Oct-2017)
Closing share price (31-Oct-2017)